reports
Lundbeck and Alder BioPharmaceuticals announce updated information in ...
Lundbeck and Alder BioPharmaceuticals announce updated information in the tender offer materials filed with SEC Updated tender offer materials provide additional summary information regarding existing Lundbeck offer terms, including existing CVR terms, and additional information regarding existing Alder director and officer share ownership Offer terms remain unchanged from commencement, with Lundbeck offering Alder stockholders upfront payment of USD 18.00 per share in cash along with one non-tradeable Contingent Value Right for USD 2.00 per share contingent on upon approval of eptinezumab ...
Alder BioPharmaceuticals® Announces First-in-Human Dosing in Phase 1 ...
Alder BioPharmaceuticals® Announces First-in-Human Dosing in Phase 1 ALD1910 Study for Preventive Treatment of Migraine ALD1910 is Alder’s first clinical candidate designed to inhibit pituitary adenylate cyclase-activating polypeptide (PACAP), a novel target in treating migraine BOTHELL, Wash., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing therapeutic antibodies for the treatment of migraine, today announced dosing of the first patient in a Phase 1 clinical study to evaluate ALD1910 as a preventive trea...
Lundbeck to acquire Alder BioPharmaceuticals – a company committed t...
Lundbeck to acquire Alder BioPharmaceuticals – a company committed to transforming migraine treatment and prevention – in a transaction valued at up to USD 1.95 billion net of cash Enhances Lundbeck’s leading portfolio of brain disease therapies with Alder’s highly complementary intravenous (IV) therapy for migraine prevention, eptinezumabEptinezumab is an investigational monoclonal antibody (mAb) for migraine prevention targeting the calcitonin gene-related peptide (CGRP) with a PDUFA action date of 21 February 2020If approved, eptinezumab will be the first-to-market IV CGRP therapy for mi...
Alder BioPharmaceuticals® to Showcase Data from Migraine Prevention P...
Alder BioPharmaceuticals® to Showcase Data from Migraine Prevention Portfolio at 19th Congress of the International Headache Society - Data analyses from clinical trials to highlight eptinezumab’s efficacy and early, sustained quality of life improvements in the prevention of chronic migraine -- Preclinical data also to be presented for ALD1910, Alder’s second candidate for migraine, demonstrating its binding and selectivity to pituitary adenylate cyclase-activating peptide - BOTHELL, Wash., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceut...
Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listi...
Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) BOTHELL, Wash., Aug. 30, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (Nasdaq: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today reported that the Compensation Committee of Alder’s Board of Directors granted an award of 11,500 restricted stock units (“RSUs”) to a new employee under Alder’s 2018 Inducement Award Plan (the “Inducement Plan”), effective August 27, 2019. One-fourth of the RSUs will vest yearly on each an...
Alder BioPharmaceuticals® to Present at Two Upcoming September Invest...
Alder BioPharmaceuticals® to Present at Two Upcoming September Investor Conferences BOTHELL, Wash., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that members of the management team will provide a business overview and update at the Wells Fargo Securities 2019 Healthcare Conference at 2:25 p.m. ET on Wednesday, September 4, 2019 in Boston, MA and at the Morgan Stanley 17th Annual Global Healthcare Conference at 4:05 p.m. ET on Tue...
Alder BioPharmaceuticals® Reports Second Quarter 2019 Financial and O...
Alder BioPharmaceuticals® Reports Second Quarter 2019 Financial and Operating Results Data presented at American Academy of Neurology and American Headache Society Annual Meetings continue to support eptinezumab’s differentiated clinical profile and impact on quality of life measures Core commercial leadership team secured, including field payer team, in anticipation of expected eptinezumab U.S. launch in 1Q 2020, assuming FDA approval Key milestones anticipated in 2H 2019, including completed commercial footprint, start of acute study and advancement of second product candidate, ALD1910...
Alder BioPharmaceuticals® Reports Inducement Grants Under Nasdaq List...
Alder BioPharmaceuticals® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOTHELL, Wash., Aug. 02, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (Nasdaq: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today reported that the Compensation Committee of Alder’s Board of Directors granted a non-qualified stock option to purchase an aggregate of 45,000 shares of Alder’s common stock and an award of 25,000 restricted stock units (“RSUs”) to a new employee under Alder’s 2018 Inducement Award Plan (the ...
Alder BioPharmaceuticals® to Present at Canaccord Genuity 39th Annual...
Alder BioPharmaceuticals® to Present at Canaccord Genuity 39th Annual Growth Conference BOTHELL, Wash., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that Bob Azelby, Alder’s president and chief executive officer, will provide a business overview and update at the Canaccord Genuity 39th Annual Growth Conference at 12:30 p.m. ET on Thursday, August 8, 2019 in Boston, MA. The presentation will be webcast live on the Events & Pres...
Alder BioPharmaceuticals® to Host Conference Call to Discuss Second Q...
Alder BioPharmaceuticals® to Host Conference Call to Discuss Second Quarter 2019 Financial and Operating Results BOTHELL, Wash., July 30, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that it will report its second quarter 2019 financial and operating results after the close of U.S. financial markets on Tuesday, August 6, 2019. Alder management will host a conference call and live audio webcast to discuss the results and provide a general ...
Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listi...
Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) BOTHELL, Wash., July 26, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (Nasdaq: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today reported that the Compensation Committee of Alder’s Board of Directors granted a non-qualified stock option to purchase an aggregate of 40,000 shares of Alder’s common stock and an award of 20,000 restricted stock units (“RSUs”) to a new employee under Alder’s 2018 Inducement Award Plan, effec...
- Dave Nicoski
- Ross LaDuke
Vermilion Short Shots: Technically Vulnerable Stocks
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
SNA SNAP-ON INCORPORATED
WTFC WINTRUST FINANCIAL CORPORATION
WSFS WSFS FINANCIAL CORPORATION
WFC WELLS FARGO & COMPANY
SPG SIMON PROPERTY GROUP INC.
PKXN POSCO
PEB PEBBLEBROOK HOTEL TRUST
FTE1 ORANGE
MSTR MICROSTRATEGY INCORPORATED CLASS A
LLY ELI LILLY AND COMPANY
IPGP IPG PHOTONICS CORPORATION
INSM INSMED INCORPORATED
ICPT INTERCEPT PHARMACEUTICALS INC.
HOO HERBALIFE NUTRITION LTD.
I3N CHART INDUSTRIES INC.
GBCI GLACIER BANCORP INC.
FMBI FIRST MIDWEST BANCORP INC.
ERICn TELEFONAKTIEBOLAGET LM ERICSSON
EBIX EBIX INC.
CXW CORECIVIC INC.
BT BT GROUP PLC ADS
BP BP PLC ADS
APA.. APA CORP.
ALDR ALDER BIOPHARMACEUTICALS INC.
AERI AERIE PHARMACEUTICALS INC.
UVE UNIVERSAL INSURANCE HOLDINGS INC.
FDP FRESH DEL MONTE PRODUCE INC.
MUR MURPHY OIL CORPORATION
CCO. CAMECO CORPORATION
CMA COMERICA INCORPORATED
DNOW NOW INC.
CHRW C.H. ROBINSON WORLDWIDE INC.
MED MEDIFAST INC.
LASR NLIGHT
Alder BioPharmaceuticals® Presents New Data on Migraine-Free Months, ...
Alder BioPharmaceuticals® Presents New Data on Migraine-Free Months, Migraine Severity and Quality of Life, Demonstrating Eptinezumab’s Clinical Profile for Migraine Prevention - Posters presented at the 2019 American Headache Society meeting highlight eptinezumab’s safety profile and suppression of calcitonin gene-related peptide (CGRP) - - New data show no migraine days experienced for six months or more in 18.1% of episodic migraine patients treated with 100 mg of eptinezumab (over a 12-month period) - - Over 50% of chronic migraine patients treated with ...
Alder BioPharmaceuticals® to Showcase 14 New Data Presentations Demon...
Alder BioPharmaceuticals® to Showcase 14 New Data Presentations Demonstrating Eptinezumab’s Migraine Prevention and Quality of Life Impact at American Headache Society Meeting Posters highlight eptinezumab’s impact in chronic and episodic migraine clinical trials, including data on migraine-free months and early, sustained reduction in chronic migraine severity BOTHELL, Wash., July 08, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that i...
Alder BioPharmaceuticals® to Webcast Upcoming Breakfast Symposium wit...
Alder BioPharmaceuticals® to Webcast Upcoming Breakfast Symposium with Key Opinion Leaders BOTHELL, Wash., June 19, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that it will webcast its upcoming breakfast symposium with key opinion leaders. The event will focus on the company’s lead commercial product candidate eptinezumab, and the evolving migraine treatment landscape, and will be held on Wednesday, June 26, 2019 from 8:30 a.m. to 10:30 ...
Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listi...
Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) BOTHELL, Wash., May 24, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (Nasdaq: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today reported that the Compensation Committee of Alder’s Board of Directors granted a non-qualified stock option to purchase an aggregate of 50,000 shares of Alder’s common stock to a new employee under Alder’s 2018 Inducement Award Plan, effective May 21, 2019. The stock option will vest with resp...
Alder BioPharmaceuticals® to Present at Two Upcoming May Investor Con...
Alder BioPharmaceuticals® to Present at Two Upcoming May Investor Conferences BOTHELL, Wash., May 14, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that members of the management team will provide a business overview and update at the 2019 RBC Capital Markets Global Healthcare Conference at 9:30 am ET on Tuesday, May 21, 2019 and at the UBS Global Healthcare Conference at 10:00 am ET on Wednesday, May 22, 2019, both in New York, NY. The ...
Alder BioPharmaceuticals® Presents New Analysis of Patient-Reported O...
Alder BioPharmaceuticals® Presents New Analysis of Patient-Reported Outcomes Following Eptinezumab Treatment for Migraine Prevention - Data presented at the 2019 American Academy of Neurology (AAN) meeting demonstrate nearly 60% of patients reported very much or much improvement in most bothersome symptoms and in overall migraine status following two treatments with eptinezumab - - Study represents first time most bothersome symptom data has been reported in a chronic migraine prevention study - BOTHELL, Wash., May 08, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALD...
Alder BioPharmaceuticals® Presents New Data Demonstrating Consistent,...
Alder BioPharmaceuticals® Presents New Data Demonstrating Consistent, Early and Robust Prevention with Eptinezumab for Episodic and Chronic Migraine across Four Clinical Trials Data presented at the 2019 American Academy of Neurology (AAN) meeting demonstrate more than 50% of patients achieved rapid onset of migraine prevention with eptinezumab on Day 1 across four clinical trials BOTHELL, Wash., May 06, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, tod...
Alder BioPharmaceuticals® Reports First Quarter 2019 Financial and Op...
Alder BioPharmaceuticals® Reports First Quarter 2019 Financial and Operating Results - FDA sets eptinezumab PDUFA date of February 21, 2020; launch expected in first quarter of 2020 - - Acute study planned for potential eptinezumab label expansion - - Conference call today at 5:00 p.m. ET - BOTHELL, Wash., May 02, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today provided a corporate update and reported its financial results ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.